Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer
This pilot clinical trial studies anastrozole in treating aromatase inhibitor musculoskeletal symptoms in female patients with stage I-III breast cancer. Anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Other: questionnaire administration
Other: laboratory biomarker analysis
Other: pharmacogenomic studies
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
|Official Title:||A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)|
- Discontinuation of treatment following development of AIMSS determined by scores on the Health Assessment Questionnaire (HAQ) instrument [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]Logistic regression will be used to test the association between having a minor allele and the log odds of discontinuation of treatment, adjusting for covariates. A Bonferroni adjustment will be used to account for the simultaneous testing of 10 SNPs; a one-sided p-value of 0.0025 will be considered statistically significant.
- Presence of SNPs in the estrogen receptor alpha (ESR), T-cell leukemia/lymphoma 1A (TCL1A), and CYP19A1 genes [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]Correlations among SNPs will be estimated, and linkage disequilibrium among pairs of SNPs will be characterized. Logistic regression models, with treatment discontinuation as the outcome variable, will be used to explore the association with SNPs, adjusting for important clinical factors.
- Proportions of patients with treatment discontinuation for any reason [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]Explored using proportional hazards models adjusting for significant genotypic and clinical predictors. Kaplan-Meier plots will be used to graphically portray the associations.
- Proportion of patients with symptoms determined not to be from other known etiologies as assessed by the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) and Breast subscale [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]Explored using proportional hazards models adjusting for significant genotypic and clinical predictors. Kaplan-Meier plots will be used to graphically portray the associations.
- Proportion of patients whose symptoms improve when the AI is discontinued [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
- Time to discontinuation of treatment [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]Explored using proportional hazards models adjusting for significant genotypic and clinical predictors. Kaplan-Meier plots will be used to graphically portray the associations.
- Time to development of symptoms [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||May 2013|
|Estimated Primary Completion Date:||January 2020 (Final data collection date for primary outcome measure)|
Experimental: Supportive care (anastrozole)
Patients receive anastrozole PO QD for 12 months.
Other Names:Other: questionnaire administration
Ancillary studiesOther: laboratory biomarker analysis
Correlative studiesOther: pharmacogenomic studies
Other Name: Pharmacogenomic Study
I. To validate previously identified associations between 10 specific single nucleotide polymorphisms (single nucleotide polymorphisms [SNPs]) and discontinuation of treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS) among women with breast cancer.
I. To determine whether other SNPs in cytochrome P450 enzymes (CYP), glucuronosyltransferases (UGT), Vitamin D, serotonin and other receptors are associated with discontinuation of treatment due to the development of severe aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
II. To determine whether other SNPs in CYP, UGT, Vitamin D, serotonin and other receptors are associated with the development of other potential complications of AI therapy.
III. To develop a gene signature that can identify patients at risk for developing severe anastrozole-related AIMSS and other potential complications of AI therapy.
IV. To determine the epidemiology and predictors of severe AIMSS and of AI discontinuation.
V. To describe patient reported outcomes for minority patients with breast cancer treated with AIs.
VI. To assess the utility of the Patient Reported Outcomes Management Information System (PROMIS) system to collect patient reported outcomes in a cooperative group study, and validate the PROMIS Physical Function 20a form in patients with AIMSS.
VII. To develop a model that incorporates patient ratings of treatment burden, fear of recurrence and adherence behaviors to describe patient decisions to continue or discontinue anastrozole.
VIII. To collect serum samples for future testing for biomarkers of AIMSS.
Patients receive anastrozole orally (PO) once daily (QD) for 12 months.
After the completion of study treatment, patients are followed up for 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01824836
|United States, Massachusetts|
|Eastern Cooperative Oncology Group||Not yet recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Vered Stearns 410-955-8804 firstname.lastname@example.org|
|Principal Investigator: Vered Stearns|
|United States, New Jersey|
|Veterans Adminstration New Jersey Health Care System||Recruiting|
|East Orange, New Jersey, United States, 07018-1095|
|Contact: Victor T. Chang 973-676-1000 email@example.com|
|Principal Investigator: Victor T. Chang|
|Principal Investigator:||Vered Stearns||Eastern Cooperative Oncology Group|